MeiraGTx Holdings plc (MGTX) AI Stock Analysis

MeiraGTx Holdings plc is a clinical stage gene therapy company dedicated to advancing treatments for severe diseases. The company specializes in therapies for ocular diseases causing inherited blindness, radiation-induced Xerostomia resulting from head and neck cancer treatment, and neurodegenerative conditions including amyotrophic lateral sclerosis (ALS) and Parkinson's disease. Its clinical pipeline includes Phase 1/2 programs targeting Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, alongside planned studies for xerostomia linked to Sjogren's syndrome. In addition to preclinical neurodegenerative research, MeiraGTx collaborates with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapies utilizing its proprietary riboswitch technology.

Between FY2021 and FY2025, MeiraGTx recorded a 5-year revenue CAGR of 39.2%, with annual revenue shifting from $37.7M in FY2021 to $81.4M in FY2025. Across this period, the company sustained annual losses, including net income of -$114.2M and an operating margin of -130.2% in FY2025 as research and development expenses reached $129.6M. For the trailing twelve months ended June 30, 2026, revenue totaled $397.5M, supported by quarterly revenue growth of 8608.6% year-over-year in the latest quarter. Trailing twelve month net profit margin was 19.9% and diluted EPS was $0.87.

As of June 30, 2026, MeiraGTx held $143.2M in cash and short-term investments against total debt of $112.3M, resulting in net cash of $30.8M. The company reported a current ratio of 3.76, total assets of $396.4M, and shareholders' equity of $215.6M, yielding a debt-to-equity ratio of 0.52. In FY2025, operating cash flow was -$46.4M, free cash flow was -$50.2M, and capital expenditures were $3.8M. Over the past five years, the company's share count increased by 112.4%.

With a market capitalization of $891.3M and an enterprise value of $1.10B, MeiraGTx trades at a trailing price-to-earnings ratio of 10.7x, below the 24.6x median of its US-listed Healthcare peers. Its forward price-to-earnings ratio of 64.1x stands above the peer group median of 17.3x, while its price-to-sales ratio of 2.2x sits below the peer median of 4.1x. Over the past year, the stock returned 14.1%, trailing the S&P 500 (SPY) return of 16.8%, and its 5-year return of -35.0% lags the index gain of 83.0%.

Wall Street analysts cover MeiraGTx with 5 Strong Buy, 2 Buy, and 1 Hold ratings. The mean price target of $27.75 represents an upside of 199.0% over the last close of $9.28. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $337.1M and EPS of $0.51. For the following fiscal year, 4 analysts estimate revenue will decline by 80.2% to $66.9M with EPS of -$1.52. The company beat EPS estimates in 2 of the last 4 quarters, and its next earnings date is November 12, 2026.

This page is an AI-written research summary of MeiraGTx Holdings plc (MGTX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: MGTX income statement, MGTX balance sheet, MGTX key metrics, MGTX analyst forecast, MGTX chart. See the MGTX stock overview for the latest quote and news.